Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20533899 | 0.95 | PI4KB (0.61) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20534205 | 0.94 | PI4KB (0.60) | PI4KBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL20533904 | 0.91 | PI4KB (0.60) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533747 | 0.88 | PI4KB (0.63) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533670 | 0.84 | PI4KB (0.52) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533595 | 0.84 | PI4KB (0.61) | PI4KBMAPTSMN1; SMN2ALDH1A1TP53 | |
| SCHEMBL20533914 | 0.84 | PI4KB (0.42) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533762 | 0.83 | PI4KB (0.56) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533718 | 0.82 | PI4KB (0.55) | PI4KBMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL20533567 | 0.81 | PI4KB (0.53) | PI4KBMAPTSMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298009-A1 | Fused Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PI4K2B, PI4KB | PI4KB 3/4885MAPT 2367/4885SMN1; SMN2 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.